Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 202

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial

Open access
Oslin, David W., Lynch, Kevin G., Shih, Mei-Chiung, Ingram, Erin P., Wray, Laura O., Chapman, Sara R., Kranzler, Henry R., Gelernter, Joel, Pyne, Jeffrey M., Stone, Annjanette, DuVall, Scott L., Lehmann, Lisa Soleymani, Thase, Michael E., PRIME Care Research Group, Aslam, Muhammad, Batki, Steven L., Bjork, James M., Blow, Frederic C., Brenner, Lisa A., Chen, Peijun, Desai, Shivan, Dieperink, Eric W., Fears, Scott C., Fuller, Matthew A., Goodman, Courtney S., Graham, David P., Haas, Gretchen L., Hamner, Mark B., Helstrom, Amy W., Hurley, Robin A., Icardi, Michael S., Jurjus, George J., Kilbourne, Amy M., Kreyenbuhl, Julie, Lache, Daniel J., Lieske, Steven P., Lynch, Julie A., Meyer, Laurence J., Montalvo, Cristina, Muralidhar, Sumitra, Ostacher, Michael J., Paschall, Gayla Y., Pfeiffer, Paul N., Prieto, Susana, Przygodzki, Ronald M., Ranganathan, Mohini, Rodriguez-Suarez, Mercedes M., Roggenkamp, Hannah, Schichman, Steven A., Schneeweis, John S., Simonetti, Joseph A., Steinhauer, Stuart R., Suppes, Trisha, Umbert, Maria A., Vassy, Jason L., Voora, Deepak, Wiechers, Ilse R., Wood, Amanda E. · 2022 · JAMA

Abstract

Importance: Selecting effective antidepressants for the treatment of major depressive disorder (MDD) is an imprecise practice, with remission rates of about 30% at the initial treatment. Objective: To determine whether pharmacogenomic testing affects antidepressant medication selection and whether such testing leads to better clinical outcomes. Design, Setting, and Participants: A pragmatic, randomized clinical trial that compared treatment guided by pharmacogenomic testing vs usual care. Participants included 676 clinicians and 1944 patients. Participants were enrolled from 22 Department of Veterans Affairs medical centers from July 2017 through February 2021, with follow-up ending November 2021. Eligible patients were those with MDD who were initiating or switching treatment with a single antidepressant. Exclusion criteria included an active substance use disorder, mania, psychosis, or concurrent treatment with a specified list of medications. Interventions: Results from a commercial pharmacogenomic test were given to clinicians in the pharmacogenomic-guided group (n = 966). The comparison group received usual care and access to pharmacogenomic results after 24 weeks (n = 978). Main Outcomes and Measures: The co-primary outcomes were the proportion of prescriptions with a predicted drug-gene interaction written in the 30 days after randomization and remission of depressive symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9) (remission was defined as PHQ-9 ≤ 5). Remission was analyzed as a repeated measure across 24 weeks by blinded raters. Results: Among 1944 patients who were randomized (mean age, 48 years; 491 women [25%]), 1541 (79%) completed the 24-week assessment. The estimated risks for receiving an antidepressant with none, moderate, and substantial drug-gene interactions for the pharmacogenomic-guided group were 59.3%, 30.0%, and 10.7% compared with 25.7%, 54.6%, and 19.7% in the usual care group. The pharmacogenomic-guided group was more likely to receive a medication with a lower potential drug-gene interaction for no drug-gene vs moderate/substantial interaction (odds ratio [OR], 4.32 [95% CI, 3.47 to 5.39]; P < .001) and no/moderate vs substantial interaction (OR, 2.08 [95% CI, 1.52 to 2.84]; P = .005) (P < .001 for overall comparison). Remission rates over 24 weeks were higher among patients whose care was guided by pharmacogenomic testing than those in usual care (OR, 1.28 [95% CI, 1.05 to 1.57]; P = .02; risk difference, 2.8% [95% CI, 0.6% to 5.1%]) but were not significantly higher at week 24 when 130 patients in the pharmacogenomic-guided group and 126 patients in the usual care group were in remission (estimated risk difference, 1.5% [95% CI, -2.4% to 5.3%]; P = .45). Conclusions and Relevance: Among patients with MDD, provision of pharmacogenomic testing for drug-gene interactions reduced prescription of medications with predicted drug-gene interactions compared with usual care. Provision of test results had small nonpersistent effects on symptom remission. Trial Registration: ClinicalTrials.gov Identifier: NCT03170362.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2022.9805

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 202

Metadata

Authors
Oslin, D. W., Lynch, K. G., Shih, M.-C., Ingram, E. P., Wray, L. O., Chapman, S. R., Kranzler, H. R., Gelernter, J., Pyne, J. M., Stone, A., DuVall, S. L., Lehmann, L. S., Thase, M. E., PRIME Care Research Group, Aslam, M., Batki, S. L., Bjork, J. M., Blow, F. C., Brenner, L. A., Chen, P., Desai, S., Dieperink, E. W., Fears, S. C., Fuller, M. A., Goodman, C. S., Graham, D. P., Haas, G. L., Hamner, M. B., Helstrom, A. W., Hurley, R. A., Icardi, M. S., Jurjus, G. J., Kilbourne, A. M., Kreyenbuhl, J., Lache, D. J., Lieske, S. P., Lynch, J. A., Meyer, L. J., Montalvo, C., Muralidhar, S., Ostacher, M. J., Paschall, G. Y., Pfeiffer, P. N., Prieto, S., Przygodzki, R. M., Ranganathan, M., Rodriguez-Suarez, M. M., Roggenkamp, H., Schichman, S. A., Schneeweis, J. S., Simonetti, J. A., Steinhauer, S. R., Suppes, T., Umbert, M. A., Vassy, J. L., Voora, D., Wiechers, I. R., & Wood, A. E.
Venue
JAMA
Published
2022-07-12
Volume
328
Issue
2
Pages
151
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W4285077243
Cited by
202
References
10
FWCI
29.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2022.9805
The paper
Oslin, D. W., Lynch, K. G., Shih, M.-C., Ingram, E. P., Wray, L. O., Chapman, S. R., Kranzler, H. R., Gelernter, J., Pyne, J. M., Stone, A., DuVall, S. L., Lehmann, L. S., Thase, M. E., PRIME Care Research Group, Aslam, M., Batki, S. L., Bjork, J. M., Blow, F. C., Brenner, L. A., . . . Wood, A. E. (2022). Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2022.9805

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.